Navigation Links
Asymmetrex Director Shares Vision for Company and Private Stem Cell Treatment Clinics in Two Arena International Event Group Forums
Date:11/17/2016

“Asymmetrex is on the path to success.” James Sherley, director of Asymmetrex, confidently spoke these words when he recounted the business development progress of the company that he founded three years earlier. Sherley was speaking at the 1st Annual Preclinical Development Operations Summit, organized by Arena International Events Group, on November 15-16, in Boston.

Developing more effective collaboration and partnership between contract research organizations (CRO) and their pharmaceutical company and cell therapy company sponsors was the major focus of the Summit. However, in addition to attendance by heads of drug development and cell therapy development from well-established companies, the Summit also included executives from new pharmaceutical and CRO start-ups. Asymmetrex, having recently launched a new contract service that provides, for the first time, tissue stem cell counting for both support of drug development and stem cell therapeutics, was invited to present. Director Sherley reviewed the company’s current business strategy and its longer-term vision of leveraging the new CRO business towards future success as an adult tissue stem cell biomanufacturing company.

Fifteen minutes before Sherley began his presentation on the first day of the Summit, at 12 pm EDT, the clinical trials news site of Arena International published a new perspective from him on the importance of private stem cell treatment clinics to the future of stem cell biomedicine. The article considers that these clinics have been generally mischaracterized regarding their motivation and their research merit. Sherley emphasizes that their presently unregulated stem cell treatments are a part of the long tradition of routine medical practice also serving as a source of scientific discovery and medical innovation. The article makes recommendations for improvements in current treatment practices in private clinics that would increase the quality of care and the utility of knowledge obtained to accelerate progress in stem cell medicine.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Currently, Asymmetrex’s focus is employing its technological advantages to develop and market facile methods for monitoring adult stem cell number and function in stem cell transplantation treatments and in pre-clinical assays for drug safety.

Read the full story at http://www.prweb.com/releases/2016/11/prweb13860131.htm.


'/>"/>
Source: PRWeb
Copyright©2016 Vocus, Inc.
All rights reserved


Related biology technology :

1. Asymmetrex Presents Technologies to Accelerate Gene-Editing Therapeutics Progress
2. Asymmetrex Continues Efforts to Raise Awareness of the Importance of Tissue Stem Cell Counting for Advancing Gene-Editing Therapeutics
3. In a Scheduled March 22 RegMedNet Webinar, Asymmetrex Discusses the Strategy for Its AlphaSTEM Technology for Counting Adult Tissue Stem Cells
4. In Upcoming Webinar and Conferences, Asymmetrex Will Intensify Education on Counting Adult Tissue Stem Cells For Regenerative Medicine and Drug Development
5. Asymmetrex Supports UK RegMedNet with Sponsorship for Education on the Importance of Counting Adult Tissue Stem Cells in Regenerative Medicine Practice
6. With Disclosure of Recently Met Benchmarks for Its Adult Tissue Stem Cell Counting Technology, Asymmetrex Targets Applications to Enable Gene-Editing Therapies
7. Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time
8. Asymmetrex Presents Its Crowdsourcing Campaign for Counting Adult Tissue Stem Cells at the 8th International Epigenetics, Stem Cells, Sequencing & SNiPs Meeting in August
9. Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer
10. Asymmetrex’s Crowdsourcing Campaign For Evaluating A First Biomarker for Counting Adult Tissue Stem Cells Is Gaining Momentum
11. Asymmetrex Introduces “The Third Dimension of Time” to 3D Cell Modelers at the 14th Annual World Preclinical Congress in Boston
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased ... of over 5.5 million people each year. Especially those living in larger cities are ... - based in one of the most pollution-affected countries globally - decided to take ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer ... treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and bind ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive ... a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
(Date:10/10/2017)... ... ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. ... event entitled “Stem Cells and Their Regenerative Powers,” was held on August 31st, ... was joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic Surgery, ...
Breaking Biology Technology:
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... grow at a CAGR of 30.37% during the period 2017-2021. ... prepared based on an in-depth market analysis with inputs from industry ... over the coming years. The report also includes a discussion of ...
(Date:4/6/2017)... , April 6, 2017 Forecasts ... ANPR, Document Readers, by End-Use (Transportation & Logistics, Government ... Oil, Gas & Fossil Generation Facility, Nuclear Power), Industrial, ... Other) Are you looking for a definitive ... ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
Breaking Biology News(10 mins):